Studies of Cross-Reactivity of Acquired Factor VIII Inhibitor Activity in Hemophilic Plasma^[*]

Summary

The plasma of a hemophilic patient with acquired factor VIII inhibitory activity was found to be time and temperature dependent, resistant to heat and stable on storage at -20°. Studies revealed cross-reactivitiy with 11 different mammalian plasmas but no cross-reaction was found with chicken plasma. The inhibitory activity of the plasma studied was neutralized by fresh normal plasma and normal serum but not by aged normal plasma or hemophilic plasma (20 patients). Comparison of the present findings with other reports suggest a difference in cross-reactivity of acquired inhibitors and inhibitory activity induced by immunization of animals.

^* This investigation was supported by a graduate training grant (TI-AM-5344) from the National Institute of Arthritis and Metabolic Diseases, and research grants from the National Heart Institute (RG-HE-07418), the National Institute of Child Health and Human Development (RG-HD-00568), National Institutes of Health, United States Public Health Service and the Chicago and Illinois Heart Associations.

• References

• 1 Abildgaard G. F, Simone J. V, Corrigan J. J, Seeler R. A, Edelstein G, Vanderheiden J, Schulman I. Treatment of hemophilia with glycine-precipitated factor VIII. New Engl. J. Med. 275: 471 1966;
• 2 Adelson E, Rheingold J. J, Parker O, Steiner M, Kirby J. C. The survival of factor VIII (antihemophilic globulin) and factor IX (plasma thromboplastin component) in normal humans. J. clin. Invest. 42: 1040 1963;
• 3 Beck E, Bachmann F, Müller J, Duckert F. Formation of an inhibitor against factor VIII as postoperative a complication in a severe case of hemophilia A. Thrombos. Diathes. haemorrh. (Stuttg) 12: 1 1964;
• 4 Biggs R, Bidwell E. A method for the study of antihaemophilic globulin inhibitors with reference to six cases. Brit. J. Haemat. 05: 379 1959;
• 5 Breckenridge R. T, Ratnojf O. D. Studies on the nature of the circulating anticoagulant directed against antihemophilic factor: With notes on an assay for antihemophilic factor. Blood 20: 137 1962;
• 6 Fantl P, Sawers R. J, Marr A. G. Investigation of haemorrhagic disease due to beta-prothromboplastin deficiency complicated by a specific inhibitor of thromboplastin formation. Aust. Ann. Med. 05: 163 1956;
• 7 Goudemand M, Foncant M, Hutin A, Parquet-Gernez A. Les anticoagulants circulants antifacteur VIII au cours de l’hémophilie A. Nouv. Rev. franç. Hémat. 03: 703 1963;
• 8 Hall M. Haemophilia complicated by an acquired circulating anticoagulant: A report of three cases. Brit. J. Haemat. 07: 340 1961;
• 9 Leitner A, Bidwell E, Dike G. W. R. An antihaemophlic globulin (factor VIII) inhibitor: Purification, characterization and reaction kinetics. Brit. J. Haemat. 09: 245 1963;
• 10 Margolius Jr. A, Jackson D. P, Ratnoff O. D. Circulating anticoagulants: A study of 40 cases and a review of the literature. Medicine 40: 145 1961;
• 11 McLester W. D, Wagner R. H. Antibody to antihemophilic factor and its lack of reaction with hemophilic plasma. Amer. J. Physiol. 208: 499 1965;
• 12 Michael S. E, Tunnah G. W. The purification of factor VIII (antihaemophilic globulin). I. Further purification and some properties of factor VIII. Brit. J. Haemat. 12: 115 1966;
• 13 Piper W, Schreir M. H. Über den immunologischen Nachweis von Faktor-VIII-Protein im Bluterplasma und seine Bedeutung für das Verständnis der Hämophilie A. Thrombos. Diathes. haemorrh. (Stuttg) 11: 423 1964;
• 14 Richards M. D, Spaet T. H. Immunization of rabbits against human antihemophilic factor. Blood 11: 473 1956;
• 15 Roberts H. R, Scales M. B, Madison J. T, Webster W. P, Penick G. D. A clinical and experimental study of acquired inhibitors to factor VIII. Blood 26: 805 1965;
• 16 Shanberge J. N, Gore I. Studies on the immunologic and physiologic activities of antihemophilic factor (AHF). J. Lab. clin. Med. 50: 945 1957;
• 17 Simone J. F, Vanderheiden J, Abildgaard G. F. A semiautomatic onestage factor VIII assay using a commercially-prepared standard. J. Lab. clin. Med. 69: 706 1967;
• 18 Sise H. S, Gauthier J, Desforges J, Becker R. Spontaneous circulating anticoagulant (antifactor VIII). Amer. J. Med. 32: 964 1962;
• 19 Spaet T. H, Kinsell B. G. A circulating anticoagulant selectively active against human antihemophilic factor (autoimmune hemophilia). Stanf. med. Bull. 12: 246 1954;
• 20 Uszynski L. The immunological properties of factor VIII. I. Studies on the inhibitory activity of specific antisera to human antihemophilic globulin. Thrombos. Diathes. haemorrh. (Stuttg) 16: 559 1966;